A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...

Feb 13 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab and partner Sanofi (SASY.PA), opens new tab will stop a late-stage trial of an experimental vaccine to prevent infections caused by the ...